Corona Remedies IPO Dec 2025: GMP, Price Band, Dates & Full Review Corona Remedies IPO is a ₹655.37 crore book-built issue, offered entirely through an Offer for Sale. This means the company will not receive any new funds. Instead, existing shareholders are selling a part of their stake. The company operates in the pharmaceutical segment with strong brands across women’s healthcare, cardio-diabetes, urology, pain management, and multispecialty therapies. Invest Now: https://www.unlistedkraft.in/blog/corona-remedies-ipo-dec-2025